ATE396274T1 - Herpes simplex virusstaemme - Google Patents

Herpes simplex virusstaemme

Info

Publication number
ATE396274T1
ATE396274T1 AT97926668T AT97926668T ATE396274T1 AT E396274 T1 ATE396274 T1 AT E396274T1 AT 97926668 T AT97926668 T AT 97926668T AT 97926668 T AT97926668 T AT 97926668T AT E396274 T1 ATE396274 T1 AT E396274T1
Authority
AT
Austria
Prior art keywords
icp27
icp4
icp0
icp22
cell lines
Prior art date
Application number
AT97926668T
Other languages
English (en)
Inventor
Neal Deluca
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24612790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE396274(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of ATE396274T1 publication Critical patent/ATE396274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C12N2710/16652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97926668T 1996-05-22 1997-05-22 Herpes simplex virusstaemme ATE396274T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/651,419 US5804413A (en) 1992-07-31 1996-05-22 Herpes simplex virus strains for gene transfer

Publications (1)

Publication Number Publication Date
ATE396274T1 true ATE396274T1 (de) 2008-06-15

Family

ID=24612790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926668T ATE396274T1 (de) 1996-05-22 1997-05-22 Herpes simplex virusstaemme

Country Status (8)

Country Link
US (1) US5804413A (de)
EP (1) EP0904395B2 (de)
JP (1) JP2001503611A (de)
AT (1) ATE396274T1 (de)
AU (1) AU733945B2 (de)
CA (1) CA2255939A1 (de)
DE (1) DE69738709D1 (de)
WO (1) WO1998015637A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223411B1 (en) * 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
WO2001010903A2 (en) * 1999-08-09 2001-02-15 Incyte Genomics, Inc. Proteases and protease inhibitors
WO2001018042A2 (en) * 1999-09-10 2001-03-15 Incyte Genomics, Inc. Apoptosis proteins
US6660259B2 (en) * 1999-12-08 2003-12-09 Onyx Pharmaceuticals, Inc. Herpes simplex virus for treating unwanted hyperproliferative cell growth
GB0001476D0 (en) * 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
JP2004507212A (ja) * 2000-03-03 2004-03-11 インサイト・ゲノミックス・インコーポレイテッド Ｇタンパク質共役受容体
EP1292678B8 (de) 2000-06-16 2009-11-04 Incyte Corporation G-protein gekoppelte rezeptoren
US7608704B2 (en) * 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
WO2002056828A2 (en) * 2000-11-29 2002-07-25 University Of Rochester Helper virus-free herpes virus amplicon particles and uses thereof
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
WO2003006658A1 (en) * 2001-07-13 2003-01-23 The General Hospital Corporation Mutant herpes simplex virus that expresses yeast cytosine deaminase
US7378492B2 (en) * 2002-02-20 2008-05-27 Incyte Corporation CD40-related receptor that binds CD40L
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
AU2003265431A1 (en) * 2002-08-13 2004-02-25 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
US20070065820A1 (en) * 2002-11-13 2007-03-22 Xin Jiang Lipid-associated molecules
US20070009516A1 (en) * 2002-11-26 2007-01-11 Tran Uyen K Immune response-associated proteins
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
JP2008518599A (ja) * 2004-10-28 2008-06-05 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 脊髄損傷疼痛のための末梢送達グルタミン酸脱炭酸酵素遺伝子治療
WO2006130806A2 (en) * 2005-06-01 2006-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Assay for agonists and antagonists of ion channels and for regulators of genetic expression
US7825231B2 (en) * 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
EP1783210A1 (de) * 2005-11-08 2007-05-09 ProBioGen AG Proteinfaktoren zur Erhöhung der Produktivität, neue Zelllinien und deren Verwendungen
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US8889622B2 (en) * 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
AU2011232435B2 (en) 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
CA2918535A1 (en) * 2013-07-17 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
WO2015066042A1 (en) 2013-10-28 2015-05-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic hsv vector
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
EA201790534A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CA2985649A1 (en) * 2015-05-13 2016-11-17 Sanofi Pasteur Biologics, Llc Icp0-mediated enhanced expression system
DK3408382T3 (da) 2016-01-27 2022-06-20 Oncorus Inc Onkolytiske virale vektorer og anvendelser deraf
US11753653B2 (en) 2016-03-25 2023-09-12 Periphagen, Inc. High-transducing HSV vectors
ES2924521T3 (es) 2016-03-25 2022-10-07 Periphagen Inc Vectores del VHS para la administración de NT3, y tratamiento de la CIPN
JP7125351B2 (ja) 2016-04-14 2022-08-24 ２セブンティ バイオ インコーポレイテッド サルベージキメラ抗原受容体システム
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CA3034094A1 (en) 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
MA46059A (fr) 2016-08-23 2019-07-03 Bluebird Bio Inc Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
WO2018049226A1 (en) 2016-09-08 2018-03-15 Bluebird Bio, Inc. Pd-1 homing endonuclease variants, compositions, and methods of use
US11530395B2 (en) 2016-10-17 2022-12-20 2Seventy Bio, Inc. TGFBetaR2 endonuclease variants, compositions, and methods of use
WO2018094244A1 (en) 2016-11-17 2018-05-24 Bluebird Bio, Inc. TGFβ SIGNAL CONVERTOR
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
DK3583203T5 (da) 2017-02-15 2024-09-02 2Seventy Bio Inc Donorreparationstemplates multiplex-genomeditering
DK3601367T3 (da) 2017-03-30 2025-01-13 Univ Queensland Kimære molekyler og anvendelse deraf
IL313037A (en) 2017-05-25 2024-07-01 2Seventy Bio Inc Cblb endonuclease variants, compositions, and methods of use
CA3106446A1 (en) 2017-07-13 2019-01-17 University Of Miami Method for managing pain
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
US12076369B2 (en) 2017-09-01 2024-09-03 The Frances Crick Institute Limited Immunoregulatory molecules and uses therefor
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
US11779654B2 (en) 2017-10-04 2023-10-10 2Seventy Bio, Inc. PCSK9 endonuclease variants, compositions, and methods of use
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
AU2019225251A1 (en) 2018-02-26 2020-10-15 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
KR102887853B1 (ko) 2018-06-14 2025-11-19 리제너론 파마슈티칼스 인코포레이티드 Cd79a 키메라 항원 수용체
EP3856761A1 (de) * 2018-09-24 2021-08-04 Krystal Biotech, Inc. Zusammensetzungen und verfahren zur behandlung des netherton-syndroms
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
AU2019397364B8 (en) 2018-12-10 2025-08-07 Novo Nordisk A/S Homing endonuclease variants
US12577547B2 (en) 2018-12-10 2026-03-17 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
EP3895052A4 (de) 2018-12-14 2022-10-26 2seventy bio, Inc. Dimerisierungsmittelregulierte immunorezeptorkomplexe
JP2022526094A (ja) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー 操作された単純ヘルペスウイルス－１（ｈｓｖ－１）ベクターおよびその使用
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
WO2021072310A1 (en) 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
EP4132955A2 (de) 2020-04-10 2023-02-15 SOLA Biosciences LLC Zusammensetzungen und verfahren zur behandlung von proteinaggregationsstörungen
MX2022013288A (es) 2020-04-28 2023-02-22 Sola Biosciences Llc Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43).
EP4161953A1 (de) 2020-06-05 2023-04-12 SOLA Biosciences LLC Zusammensetzungen und verfahren zur behandlung von synukleinopathien
KR20230042263A (ko) 2020-06-09 2023-03-28 이노자임 파마, 인코포레이티드 가용성 enpp1 또는 enpp3 단백질 및 이의 사용
AU2021367952A1 (en) 2020-10-26 2023-06-08 Sola Biosciences Llc Compositions and methods for the treatment of alzheimer's disease
US20240342215A1 (en) 2021-07-14 2024-10-17 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
US20250042958A1 (en) 2021-10-08 2025-02-06 Sola Biosciences Llc Compositions and methods for the treatment of proteopathies
JP2024537178A (ja) 2021-10-08 2024-10-10 ソラ・バイオサイエンシズ・エルエルシー ｐ５３媒介性癌の処置のための組成物および方法
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
JP2025513801A (ja) 2022-04-08 2025-04-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多部位受容体及びシグナル伝達複合体
EP4596687A1 (de) 2022-09-30 2025-08-06 The University of Tokyo Auf il13ra2 abzielendes herpes-simplex-virus und anti-il13ra2-antikörper oder antigenbindendes fragment davon
WO2025153530A1 (en) 2024-01-16 2025-07-24 Novo Nordisk A/S Albumin-targeted endonucleases, compositions, and methods of use
WO2025187175A1 (ja) * 2024-03-07 2025-09-12 国立研究開発法人産業技術総合研究所 組換え単純ヘルペスウイルスベクターを製造するための細胞、及び組換え単純ヘルペスウイルスベクターの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1995013391A1 (en) * 1993-11-10 1995-05-18 University Of British Columbia Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1
US5698431A (en) * 1995-02-09 1997-12-16 Washington University Herpes simplex virus mutant UL41NHB

Also Published As

Publication number Publication date
EP0904395B1 (de) 2008-05-21
EP0904395B2 (de) 2011-07-27
AU733945B2 (en) 2001-05-31
EP0904395A1 (de) 1999-03-31
CA2255939A1 (en) 1998-04-16
JP2001503611A (ja) 2001-03-21
DE69738709D1 (de) 2008-07-03
WO1998015637A1 (en) 1998-04-16
AU3137997A (en) 1998-05-05
US5804413A (en) 1998-09-08

Similar Documents

Publication Publication Date Title
ATE396274T1 (de) Herpes simplex virusstaemme
Messerle et al. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome
HUP9802538A2 (hu) Vektorok és eljárások helyspecifikus rekombináció előidézésére
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
EP1923467A3 (de) Adenovirusvektoren für die Gentherapie
DE3585900D1 (en) Enhancer fuer eukaryotische expressionssysteme.
DE69816647D1 (de) Methode zur erhöhung der effizienz gerichteter evolution eines gens mittels phagemiden
WO1995027071A3 (en) An adenovirus supervector system
GB9709728D0 (en) Single step method
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
ES2255281T3 (es) Sobreexpresion de genes de fitasa en sistmas de levadura.
CA2179656A1 (en) Chromosomal expression of heterologous genes in bacterial cells
Leiden et al. Identification of the herpes simplex virus DNA sequences present in six herpes simplex virus thymidine kinase-transformed mouse cell lines
CA2263713A1 (en) Lyophilization of cultured human cells to preserve rna and dna
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
FI962268A0 (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
IE840258L (en) Expression of gene products.
MXPA98003564A (es) Genes de des-epoxidasa de violaxantina de planta ysus metodos relacionados.
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU5318496A (en) Adenovirus vectors for gene therapy
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
FR2563533B1 (fr) Procede d'amplification de l'expression d'un gene determine chez bacillus subtilis et souches obtenues
AU2362795A (en) Introduction of HIV-protective genes into cells by particle-mediated gene transfer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties